Third Phase II Trial Initiated by Myriad For Azixa(TM)
TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.
Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.
"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."
Myriad is responsible for the worldwide development and
commercialization of Azixa and any drug candidate that is developed from
the series of compounds licensed by EpiCept to Myriad in 2003. The
agreement requires that Myriad make future licensing, research and
milestone payments to EpiCept, as well as pay a portion of any sublicensing
income and pay a royalty on product sales. EpiCept will earn a milestone
payment upon the dosing of the first patient in a Phas
|SOURCE EpiCept Corporation|
Copyright©2007 PR Newswire.